Efavirenz-Based Regimens in Antiretroviral-Naive HIV-Infected Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Joanna Kryst, Paweł Kawalec, Andrzej Pilc

Abstract

Efavirenz, a non-nucleoside reverse-transcriptase inhibitor (NNRTI) is one of the most commonly prescribed antiretroviral drugs. The present article provides a systematic overview and meta-analysis of clinical trials comparing efavirenz and other active drugs currently recommended for treatment of HIV-infected, antiretroviral-naive patients. Electronic databases (Pubmed, Embase, the Cochrane Library, Trip Database) were searched up till 23 December 2013 for randomized controlled clinical trials published as a peer-reviewed papers, and concerning efavirenz-based regimens used as initial treatment for HIV infection. Thirty-four studies were included in the systematic review, while twenty-six trials were suitable for the meta-analysis. Efavirenz was compared with drugs from four different classes: NNRTIs other than efavirenz (nevirapine or rilpivirine), integrase strand transfer inhibitors (InSTIs), ritonavir-boosted protease inhibitors (bPI) and chemokine (C-C motif) receptor 5 (CCR5) antagonists (maraviroc), all of them were added to the background regimen. Results of the current meta-analysis showed that efavirenz-based regimens were equally effective as other recommended regimens based on NNRTI, ritonavir-boosted PI or CCR5 antagonist in terms of efficacy outcomes (disease progression and/or death, plasma viral HIV RNA <50 copies/ml) while statistically significant more patients treated with InSTI-based or CCR5-based therapy achieved plasma viral load <50 copies/ml at week 48. In comparison with both InSTI-based and CCR5-based therapy, efavirenz-based treatment was associated with a higher risk of therapy discontinuation due to adverse events. However, comparisons of efavirenz-based treatment with InSTI-based and CCR5-based therapy were based on a limited number of trials, therefore, conclusions from these two comparisons must be confirmed in further reliable randomized controlled studies. Results of our meta-analysis support the present clinical guidelines for antiretroviral-naive, HIV-infected patients, in which efavirenz is one of the most preferred regimens in the analyzed population. Beneficial safety profile of InSTI-based and CCR5-based therapy over efavirenz-based treatment needs further studies.
Introduction
Highly-active antiretroviral therapy (HAART) with three or more antiretroviral drugs is nowadays a “gold standard” of HIV treatment. HAART has been shown to reduce morbidity and mortality in HIV-infected patients [1–2]. Results from recent studies show that about 80% of treatment-naive patients reached plasma HIV RNA level below detection limit after 48 weeks of HAART therapy (when intent-to-treat (ITT) approach was applied) [3–4]. Currently investigated treatment options concerning new classes of drugs, such as for example chemokine (C-C motif) receptor 5 (CCR5) antagonists and integrase inhibitors (InSTI) may improve efficacy outcomes in HIV-infected patients. Efavirenz belongs to the class of non-nucleoside reverse-transcriptase inhibitors (NNRTIs) and is one of the most commonly prescribed antiretroviral medications in the world [5]. The efficacy and safety of efavirenz were assessed in numerous head-to-head randomized controlled trials (RCTs). Its effectiveness in antiretroviral-naive and treatment-exposed HIV-infected patients was compared with various regimens (mostly PI-based), however there is still a lack of comprehensive review regarding comparison of efavirenz-based therapy with other, actually recommended regimens. Recent practice guidelines of initial treatment in HIV-infected patients, among preferred combinations of antiretroviral drugs mentioned two nucleoside reverse transcriptase inhibitors (NRTIs) plus either a non-nucleoside reverse-transcriptase inhibitor (NNRTI), ritonavir-boosted protease inhibitor (ritonavir-boosted PI) or integrase strand transfer inhibitor (InSTI) [6–8]. In some circumstances, a CCR5 antagonist in combination with two NRTIs are also recommended [6–7]. In the light of numerous trials regarding the use of efavirenz in HIV-infected, antiretroviral-naive patients, we performed systematic review and meta-analysis of randomized controlled trials in order to establish differences between efavirenz-based regimens and other regimens recommended by clinical experts to be used in HIV-infected patients previously untreated with antiretroviral therapy.

Methods
This review was performed in accordance with the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines [9] and methods described in the Cochrane Handbook [10]. A systematic search of electronic databases and reference lists of all eligible studies published up till 23 December 2013 was conducted in order to identify all relevant studies. The search was conducted in the following databases: Medline via PubMed, EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL), and the Trip Database. The search strategy included MeSH and EMTREE terms combined the with boolean logical operators AND and OR (Table 1). The search results were restricted to clinical studies and methodological filters were used for the selection of randomized controlled trials (RCTs). No limits were applied for language of articles. The Cochrane Database of Systematic Reviews, PubMed and EMBASE databases were also searched for review articles. We included all randomized controlled trials published as a full text comparing efavirenz with any other, commonly used treatment schedule in adult HIV-infected patients without prior exposure to antiretroviral therapy (studies assessing placebo as a comparator were excluded). Data presented only at conference meetings in abstract form were not included in the systematic review and meta-analysis, as the reliability of such results is lower than published peer-reviewed references. We also excluded studies where efavirenz was administered to patients in every treatment arm, trials conducted only on children and infants and carried out in HIV-infected patients with other concurrent infectious illnesses, like hepatitis B, hepatitis C or tuberculosis. The following outcomes were assessed: (i) progression of disease or death, (ii) virological response to treatment,
and (iii) safety profile (defined as risk of adverse events and discontinuation of the treatment due to adverse events).

Two reviewers (J.K., P.K.) performed an independent search and selection process. Disagreements were resolved by discussion, consensus, and arbitration by the third author (A.P.). Full texts of articles were reviewed according to the predefined inclusion or exclusion criteria. The second reviewer (P.K.) verified data extracted by the first author (J.K.). The following data were extracted: study design, characteristics of study participants, interventions, duration of treatment and clinical outcomes. We used Jadad scale [11] (which evaluates studies based on their description of randomization, blinding, and dropouts) to assess the methodological quality of the included studies (Table 2).

Reduction of Risk Ratio (RR) was obtained for data showing the benefit of treatment, while for negative endpoints, the increase in RR was assessed, all with 95% confidence intervals (CI). The results obtained from separate trials were combined using appropriate meta-analysis methods. If possible, data from intention-to-treat (ITT) analyses, which assessed patients according to their assigned treatment group were extracted. An inverse variance and the Mantel-Haenszel or DerSimonian-Laird methods were used in dependence on the data input and heterogeneity of test results. The clinical heterogeneity was assessed by examining the characteristics of the studies, whereas the statistical heterogeneity was assessed using the Chi-square test, with a significance level p<0.10. A fixed effects model was used when no statistical heterogeneity was detected, otherwise the random effects model was used. Meta-analysis was performed with RevMan V 5.2 software.
Results

The electronic searches yielded 766 items after duplicates were removed. The selection of titles and abstracts resulted in 107 potentially relevant articles, of which 64 references were excluded due to the reasons presented in Fig 1. Finally 34 studies described in 44 references met the

Table 2. Methodological quality of included RCTs.

| Study (acronym if stated) | Jadad score | Allocation concealment |
|--------------------------|-------------|------------------------|
|                          | 1 | 2 | 3 | 4 | 5 | Total |
| [15] Cohen 2011, THRIVE   | 1 | 0 | 1 | 1 | 1 | 4 | Not reported |
| [16] Gaytán 2004         | 1 | 0 | 0 | 0 | 0 | 1 | Not reported |
| [17] Gazzard 2011, [18] Nelson 2011, SENSE | 1 | 0 | 1 | 1 | 1 | 4 | Not reported |
| [19] Molina 2011, ECHO    | 1 | 0 | 1 | 1 | 1 | 4 | Not reported |
| [20] Nunez 2002, SENC     | 1 | 0 | 0 | 0 | 1 | 2 | Not reported |
| [21] Pozniak 2010, TMC278-C204 | 1 | 0 | 0 | 0 | 1 | 2 | Not reported |
| [22] van den Berg-Wolf 2008, substudy of FIRST [23] | 1 | 0 | 0 | 0 | 0 | 1 | Not reported |
| [24] van Leth 2004, 2NN    | 1 | 0 | 0 | 0 | 1 | 2 | Not reported |
| [25] Vernazza 2013, A5271015 | 1 | 0 | 1 | 0 | 1 | 3 | Not reported |
| [26] Wester 2010, TSHEPO   | 1 | 0 | 0 | 0 | 1 | 2 | Not reported |
| [28] Cohen 2011, GS-236-014 | 1 | 0 | 1 | 1 | 1 | 4 | Not reported |
| [29] Lennox 2009, [30] Lennox 2010, STARTMRK | 1 | 0 | 1 | 1 | 1 | 4 | Described |
| [31] Markowitz 2007, [32] Markowitz 2009, Protocol 004 | 1 | 0 | 1 | 1 | 1 | 4 | Not reported |
| [33] Sax 2012, [34] Zolopa 2013, GS-US-236-0102 | 1 | 0 | 1 | 1 | 1 | 4 | Described |
| [35] van Lunzen 2012, [36] Stellbrink 2013, SPRING-1 | 1 | 0 | 0 | 0 | 1 | 2 | Not reported |
| [37] Walmsley 2013, SINGLE | 1 | 0 | 1 | 1 | 1 | 4 | Not reported |
| [38] Albini 2012          | 1 | 0 | 0 | 0 | 1 | 2 | Not reported |
| [39] Bartlett 2006, CLASS  | 1 | 0 | 0 | 0 | 1 | 2 | Not reported |
| [40] Cameron 2008, M03-613 | 1 | 0 | 0 | 0 | 1 | 2 | Not reported |
| [41] Daar 2011, A5202     | 1 | 0 | 0 | 0 | 1 | 2 | Described |
| [42] Echeverría 2010, LAKE | 1 | 0 | 0 | 0 | 1 | 2 | Not reported |
| [43] Honda 2011           | 1 | 0 | 0 | 0 | 1 | 2 | Not reported |
| [44] Josephson 2010, [45] Edén 2010, [46] Andersson 2013, NORTIV | 1 | 0 | 0 | 0 | 1 | 2 | Not reported |
| [47] Kumar 2013, SUPPORT  | 1 | 0 | 0 | 0 | 1 | 2 | Not reported |
| [48] Mallolas 2008, TRIZEFAL | 1 | 0 | 0 | 0 | 1 | 2 | Not reported |
| [49] Miró 2010, ADVANZ     | 1 | 0 | 0 | 0 | 1 | 2 | Not reported |
| [50] Puls 2010, ALTAIR     | 1 | 0 | 0 | 0 | 1 | 2 | Not reported |
| [51] Ratsela 2010, PHISIDA II | 1 | 0 | 0 | 0 | 1 | 2 | Not reported |
| [52] Riddler 2008, A5142   | 1 | 0 | 0 | 0 | 1 | 2 | Not reported |
| [53] Sierra-Madero 2010    | 1 | 0 | 0 | 0 | 1 | 2 | Not reported |
| [54] Torti 2005, [55] Torti 2008 | 1 | 0 | 0 | 0 | 1 | 2 | Not reported |
| [56] Copper 2010, [57] Sierra-Madero 2010, MERIT | 1 | 0 | 1 | 0 | 1 | 3 | Not reported |
| [58] Currier 2008, ASCENT  | 1 | 0 | 0 | 0 | 1 | 2 | Not reported |
| [59] Landovitz 2008       | 1 | 0 | 1 | 0 | 1 | 3 | Not reported |

1—Was the study described as randomized?
2—Was the method of randomization described and appropriate?
3—Was the study described as double blind?
4—Was the method of blinding described and appropriate?
5—Were withdrawals and dropouts described?

doi:10.1371/journal.pone.0124279.t002
predefined inclusion criteria. Twenty-six RCTs were suitable for quantitative synthesis (meta-analysis). The flow of information through the different phases of the systematic review is shown in Fig 1.

Thirty-four randomized controlled trials published in English as peer-reviewed articles were included. These included studies were grouped in the following way. Firstly, background regimen, common in compared groups, was identified. Active drugs added to the common background regimen were considered as comparators. Two different regimens adequate for comparisons with efavirenz were identified: NNRTI (non-nucleoside reverse transcriptase inhibitor), InSTI (integrase strand transfer inhibitor), bPI (ritonavir-boosted protease inhibitor), and CCR5 (CC chemokine receptor type 5), all added to the specified background regimens.

Fig 1. PRISMA flow diagram for selection of studies identified in the systematic review.

doi:10.1371/journal.pone.0124279.g001
We did not take into consideration regimens containing unboosted PI and triple NRTIs regimens as they are no longer used in the clinical practice.

The predefined inclusion criteria for studies included the absence of any prior treatment with antiretroviral therapy, however finally, trials recruiting patients with limited previous exposure to antiretroviral therapy were included (Table 3). Both patient-important endpoints (AIDS disease progression and/or death) and surrogate endpoints (virological response measured with plasma HIV RNA level, pVL) were extracted from the studies. Plasma viral load (pVL) is a globally accepted endpoint used to measure the efficacy of antiretroviral drugs [12]. In the included studies, the virological response was defined as plasma HIV RNA level below 400 and below 50 copies/ml. We assessed only the pVL<50 copies/ml, as the suppression of pVL to 50 copies/ml is a better predictor for durable virological success than a suppression to <400–500 copies/ml [13–14]. For safety analysis an overall risk of grade 3/4 adverse events was assessed when it was possible; otherwise clinical adverse events data were included. We also evaluated the risk of discontinuation of assigned treatment due to treatment toxicity.

The characteristics of the included studies are presented in Table 3. Eleven studies were double-blind. Only four of the included studies provided information about allocation concealment. Most of the trials reported data about patient withdrawals and drop-outs from the study. Jadad scores ranged from 1 to 4, mostly due to a lack of blinding and insufficient data about randomization methods used (Table 2).

**Effectiveness of adding efavirenz vs non-nucleoside reverse transcriptase inhibitor (NNRTI) to the background regimen**

Ten studies were suitable for inclusion in the comparison of efavirenz vs. other NNRTI added to the background regimen: THRIVE [15], Gaytán [16], SENSE [17–18], ECHO [19], SENC [20], TMC278-C204 [21], NNRTI substudy [22] of the FIRST trial [23], 2NN [24], A5271015 [25], TSHEPO [26]. Nevirapine was used as a comparator in five studies [16,20,22,24,26], rilpivirine in three studies [15,19,21], while one study accessed etravirine [17–18], and one study included lersivirine as a comparator [25]. Data from SENSE trial [17–18] were excluded from meta-analysis because etravirine, according to the current guidelines, is not recommended as an initial therapy in HIV-infected patients, due to the insufficient data in antiretroviral-naive patients [6]. We also did not include results of A5271015 [25] study, because the clinical development of lersivirine for the treatment of HIV infection was discontinued in February 2013. With regard to TSHEPO [26] study, it was not possible to meta-analyze the outcomes due to their inconsistency with other trials. In FIRST substudy [22] and TMC278-C204 study [21], previous limited exposure to antiretroviral therapy was permitted (Table 3). In nevirapine studies, three of them evaluated patients during the course of 48 weeks while in two trials the follow-up period lasted 3 to 5 years (median). In all three studies, where rilpivirine was given to HIV-infected patients the follow-up period lasted 96 weeks. Studies were heterogeneous regarding baseline plasma HIV RNA level (>500 to >55 000 copies/ml). In two trials (Gaytán [16] and FIRST substudy [22]) it was unclear whether the efficacy results were obtained in ITT (intention-to-treat) population. Data for nevirapine given at different doses in two arms in the 2NN study [24] were aggregated. TMC278-C204 study [21] assessed rilpivirine at three doses: 25, 75 and 150 mg, however, data concerning only 25 mg dose were used in the meta-analysis, according to product characteristics [27]. No statistically significant differences between efavirenz and other NNRTI were observed when the primary efficacy endpoint—death was analyzed (RR = 1.06; 95% CI: 0.66–1.68; p>0.05), or composite outcome—disease progression or death was evaluated (RR = 1.28; 95% CI: 0.86–1.90; p>0.05). There were no statistically significant differences between analyzed groups in the proportion of patients with virological response at
Table 3. Characteristics of the randomized controlled trials for efavirenz compared to different regimens used to treat antiretroviral–naive HIV-infected adult patients.

| Study author, year of publication, study type, sites | Population | Study duration | Interventions* |
|---------------------------------------------------|------------|----------------|----------------|
| background regimen (2 NRTIs/2 NRTIs+1 PI) + efavirenz vs background regimen + NNRTI |
| [15] Cohen 2011, THRIVE, RCT, double-blind, double-dummy, 98 centers in 21 countries (United States and Puerto Rico, Canada, Australia, Europe, South Africa, Asia, Latin America) | ART-naive, age ≥18 years, pVL >5 000 copies/ml | 96 weeks | A: 2 NRTI + EFV, N = 340; B: 2 NRTI + RPV, N = 340; (2 NRTI included: TDF + FTC or AZT + 3TC or ABC + 3TC) |
| [16] Gaytán 2004, RCT, open-label, 1 center in Mexico | ART-naive, age ≥18 years, pVL >55 000 copies/ml | 48 weeks | A: AZT + 3TC + EFV, N = 30; B: AZT + 3TC + NVP, N = 28 |
| [17] Vernazza 2013, A5271015, RCT, double-blind, centers in Argentina, Australia, Europe, South Africa and Thailand | ART-naive, age ≥18 years (≤2 weeks treatment with NRTI and/or PI was allowed), pVL >5 000 copies/ml | 96 weeks | A: 2 NRTI + EFV, N = 89; B: 2 NRTI + RPV, N = 279 (25 mg N = 93, 75 mg N = 95, 150 mg N = 91); (2 NRTI included: TDF + FTC or AZT + 3TC) |
| [20] Núñez 2002, SENC, RCT, open-label, 1 center in Spain | ART-naive, age >18 years, pVL: 500–100 000 copies/ml | 48 weeks | A: ddl + d4T + EFV, N = 31; B: ddl + d4T + NVP, N = 36 |
| [21] Pozniak 2010, TMG278-C204, RCT, open-label, 54 centers in 14 countries (Asia, South Africa, Uganda, Europe, United States, Russia, Puerto Rico, Latin America) | ART-naive, age ≥18 years (<2 weeks treatment with NRTI and/or PI was allowed), pVL >5 000 copies/ml | 96 weeks | A: 2 NRTI + EFV, N = 89; B: 2 NRTI + RPV, N = N = 279 (25 mg N = 93, 75 mg N = 95, 150 mg N = 91); (2 NRTI included: TDF + FTC or AZT + 3TC) |
| [22] van den Berg-Wolf 2008, NNRTI substudy of FIRST trial [23], RCT, open-label, 17 clinical trials units at 80 sites in the United States | ART-naive (less than 4 weeks of prior NRTI use or 1 week of 3TC use was allowed), age ≥13 years | median—5 years | patients randomized to NNRTI+NNRTIs strategy (N = 110) or PI+NNRTI+PIR strategy (118) and then randomized to: A: EFV, N = 111; B: NVP, N = 117 (NNRTIs included: ABC + 3TC or ddl + d4T or AZT + 3TC or d4T + 3TC; PI included: NFV, INV, |
Table 3. (Continued)

| Study author, year of publication, study type, sites | Population | Study duration | Interventions* |
|---------------------------------------------------|------------|----------------|---------------|
| Sax 2012, [34] Zolopa 2013, GS-US-236-0102, RCT, double-blinded, centers in North America | ART-naive, age ≥18 years, pVL ≥5 000 copies/ml | 96 weeks | A: FTC + TDF + EFV, N = 354; B: FTC + TDF + EVG + COBI, N = 353 |
| van Lunzen 2012, [36] Stellbrink 2013, SPRING-1, RCT, open-label (only dose but not drug allocation was masked), 34 sites in France, Germany, Italy, Russia, Spain, and the United States | ART-naive (up to 10 days of ART was permitted), age ≥18 years, pVL>1 000 copies/ml | 96 weeks | A: 2 NRTI + EFV, N = 50; B: 2 NRTI + DTG (10 mg N = 53, 25 mg N = 51, 50 mg N = 51); (2 NRTI included: TDF + FTC or ABC + 3TC) |
| Daar 2011, A5202, RCT, open-label, centers in Canada, United States and Puerto Rico | ART-naive, pVL > 1 000 copies/ml | 48 weeks | A: TDF + FTC + EFV, N = 419; B: ABC + 3TC + DTG, N = 414 |
| Cameron 2008, M03-613, RCT, open-label, centers in United States | ART-naive, age ≥18 years, pVL ≥1 000 copies/ml | 60 weeks | background regimen (2 or 3 NRTIs) + efavirenz vs background regimen + bPI |
| Albini 2012, RCT, open-label, 4 centers in Italy | ART-naive, age ≥18 years | 48 weeks | A: TDF + FTC + EVG, N = 43; B: TDF + FTC + ATV/r, N = 48 |
| Bartlett 2006, CLASS, RCT, open-label, centers in United States | ART-naive (less than 2 weeks of prior ART), pVL ≥ 5 000 copies/ml | 96 weeks | A: ABC + 3TC + EFV, N = 97; B: ABC + 3TC + APV/r, N = 96 |
| Cameron 2008, M03-613, RCT, open-label, centers in Spain and United States | ART-naive, age ≥18 years | 96 weeks | A: AZT + 3TC + EFV, N = 51; B: AZT + 3TC + LPV/r, N = 104 |
| Daar 2011, A5202, RCT, open-label (only NRTI treatment was blinded), 59 centers in the United States and Puerto Rico | ART-naive (up to 7 days of ART was allowed), age ≥16 years | median—138 weeks | A: 2 NRTI + EFV, N = 929; B: 2 NRTI + ATV/r, N = 928; 2 NRTI included: ABC + 3TC or TDF + FTC*** |
| Echeverría 2010, LAKE, RCT, open-label, 19 centers in Spain and Italy | ART-naive, age ≥18 years | 48 weeks | A: ABC + 3TC + EFV, N = 63; B: ABC + 3TC + LPV/r, N = 63 |
| Honda 2011, RCT, open-label, 1 center in Japan | ART-naive, CD4+ T lymphocyte 100–300 cell/mm3, men only | 96 weeks | A: 3TC + ABC + EFV, N = 36; B: 3TC + ABC + ATV/r, N = 35 |
| Josephson 2010, [45] Edén 2010, [46] Andersson 2013, NORTIV, RCT, open-label, centers in Sweden and Norway | ART-naive, age ≥16 years | 144 weeks | A: 2 NRTI + EFV, N = 78 [46]; B: 2 NRTI + ATV/r, N = 82 [46]; C: 2 NRTI + LPV/r, N = 83 [46]; 2 NRTI included: ABC + 3TC or TDF + FTC or AZT + 3TC or others |
| Kumar 2013, SUPPORT, RCT, open-label, centers in United States | ART-naive (≤14 days of treatment with any ART), pVL > 5 000 copies/ml | 96 weeks | A: ABC + 3TC + EFV, N = 50; B: ABC + 3TC + FPV/r, N = 51 |
| Mallolas 2008, TRIZEFAL, RCT, open-label, 18 centers in Spain | ART-naive, pVL > 10 000 copies/ml | 72 weeks | A: ABC + 3TC + AZT + EFV, N = 109 (N = 104 were analyzed); B: ABC + 3TC + AZT + LPV/r, N = 111 (N = 105 were analyzed) |
| Miró 2010, ADVANZ, RCT, open-label, 6 centers in Spain | ART-naive, age ≥18 years, CD4+ T lymphocyte < 100 cells/μl | 36 months | A: AZT + 3TC + EFV, N = 35; B: AZT + 3TC + IDV/r, N = 35 |
| Puls 2010, ALTAIR, RCT, open-label, 36 centers in Australia, Thailand, Argentina, France, Singapore and United Kingdom | ART-naive, age ≥18 years, pVL > 2 000 copies/ml | 48 weeks | A: TDF + FTC + EFV, N = 115; B: TDF + FTC + ATV/r, N = 107 |
| Ratsela 2010, PHISIDA II, RCT, open-label, 6 centers in the Republic of South Africa | ART-naive (less than 7 days of ART was allowed), age ≥14 years, CD4+ T lymphocyte < 200 cell counts | median— 24.7 months | A: 2 NRTI + EFV, N = 888; B: 2 NRTI + LPV/r, N = 883; 2 NRTI included: AZT + ddl or d4T + 3TC |
| Riddler 2008, A5142, RCT, open-label, centers in United States, centre in Dublin and Durban | ART-naive, age ≥13 years, pVL ≥ 2 000 copies/ml | 96 weeks | A: 2 NRTI + EFV, N = 250; B: 2 NRTI + LPV/r, N = 253; (2 NRTI included: 3TC and: AZT or d4T or TDF) |
| Sierra-Madero 2010, RCT, open-label, 10 centers in Mexico | ART-naive, age ≥18 years, pVL ≥ 1 000 copies/ml | 48 weeks | A: AZT + 3TC + EFV, N = 95; B: AZT + 3TC + LPV/r, N = 94 |
| Torti 2005, [55] Torti 2008, substudy of SISTER, RCT, open-label, 1 center in Italy | ART-naive, pVL ≥ 1 000 copies/ml | 52 weeks | A: TDF + 3TC + EFV, N = 37 [55], N = 10 [54]; B: AZT + 3TC + LPV/r, N = 27 [55], N = 9 [54]; C: TDF + ddl + EFV#, N = 11 [54] |

background regimen (2 or 3 NRTIs) + efavirenz vs background regimen + CCR5

(Continued)
Table 3. (Continued)

| Study author, year of publication, study type, sites | Population | Study duration | Interventions* |
|--------------------------------------------------|------------|----------------|----------------|
| [56] Copper 2010, [57] Sierra-Madero 2010, MERIT, RCT, double-blinded, double-dummy, centers in North and South America, Europe, South Africa, and Australia | ART-naive, age ≥16 years, pVL ≥2 000 copies/ml | 96 weeks## | A: AZT + 3TC + EFV, N = 361; B: AZT + 3TC + MVC, N=360 |
| [58] Currier 2008, ASCENT, RCT, partially double-blinded, 33 centers in United States, 4 in Canada and 24 in European Union | ART-naive, age ≥13 years, pVL ≥10 000 copies/ml | 96 weeks### | A: 3TC + AZT + EFV, N = 29; B: 3TC + AZT + APL (600 mg N = 58, 800 mg N = 58) |
| [59] Landovitz 2008, RCT, double-blinded (centers not described) | ART-naive (less than 2 weeks of ART was allowed, patients in VCV arm received VCV for 14 days in monotherapy), age ≥18 years, pVL ≥5 000 copies/ml | 48 weeks | A: AZT + 3TC + EFV, N = 24; B: AZT + 3TC + VCV, N = 68 (all doses combined) |

3TC—lamivudine, ABC—abacavir, APL—aplaviroc, APV—amprenavir, ART—antiretroviral therapy, ATV—atazanavir, AZT—zidovudine, bid—twice a day, bPI—ritonavir-boosted protease inhibitor, CCR5—CC chemokine receptor type 5, COBI—cobicistat, d4T— stavudine, ddC—zalcitabine, ddl—didanosine, DTG—dolutegravir, EFV—efavirenz, ETV—etravirine, EVG—elvitegravir, FVP—fosamprenavir, FTC—emtricitabine, IDV—indinavir, MVC—maraviroc, LPV—lopinavir, LRV—lersivirine, NFV—nefllavir, NRTI—non-nucleoside reverse transcriptase inhibitor, NRTI—nucleoside reverse transcriptase inhibitor, NVP—nevirapine, PI—protease inhibitor, r—ritonavir, RAL—raltegravir, RCT—randomized controlled trial, RPV—rilpivirine, SQV—saquinavir, TDF—tenofovir, pVL—plasma HIV RNA, VCV—vicriviroc.

*interventions included in meta-analysis only.
**raltegravir monotherapy did not influence the efficacy results, so both groups (pretreated and not pretreated with raltegravir were combined).
***results for groups assigned EFV with different NRTIs and separately ATV/r + different NRTIs were combined.

#enrolment in the TDF + ddi + EFV arm was stopped as soon as the high rate of virological failure was recognized.
##once-daily MVC arm was discontinued prematurely and not analyzed.
###stopped prematurely due to unexpected hepatotoxicity.

doi:10.1371/journal.pone.0124279.003

weeks 48–52 (plasma viral loads below 50 copies/ml: RR = 1.00; 95% CI: 0.96–1.04; p>0.05). Results of meta-analysis showed that the risk of discontinuation of assigned treatment due to intolerance was comparable in both arms, without statistically significant differences (RR = 1.01; 95% CI: 0.82–1.24; p>0.05), Fig 2. It should be noticed that although data from SENSE trial [17–18] were excluded from the above comparisons, we also tested whether inclusion of the data from this trial can change the cumulative effect. We found similar results on efficacy and safety based on cumulative data, regardless of the inclusion results from SENSE trial (data not shown).

Effectiveness of adding efavirenz vs integrase strand transfer inhibitor (InSTI) added to the background regimen

Six trials were included in the comparison between efavirenz and integrase strand transfer inhibitors added to the background regimen in the treatment of HIV-infected antiretroviral-naive patients: GS-236-014 [28], STARTMRK [29–30], Protocol 004 part II [31–32], GS-US-236-0102 [33–34], SPRING-1 [35–36] and SINGLE [37]. In the two trials, raltegravir was used as an InSTI [29–32], in the next two trials, elvitegravir in combination with cobicistat (a potent CYP 3A inhibitor that increases concentration of elvitegravir, and has no antiviral activity itself) were applied [28], [33–34], two studies assessed dolutegravir as an InSTI [35–37]. Results of Protocol 004 part II, STARTMRK, GS-US-236-0102 and SPRING-1 were reported separately for 48-week and 96-week follow-up period. Previous limited exposure to HAART was permitted in two trials: Protocol 004 part II [31–32], and SPRING-1 [35–36]. Four trials provided 96-week results: Protocol 004 part II, STARTMRK, GS-US-236-0102 and SPRING-1, while
### death

| Study or Subgroup     | efavirenz Events | Total | NNRTI Events | Total | Weight | Risk Ratio M-H, Fixed, 95% CI | Risk Ratio M-H, Fixed, 95% CI |
|-----------------------|------------------|-------|--------------|-------|--------|------------------------------|------------------------------|
| Cohen 2011 THRIVE     | 3                | 338   | 1            | 340   | 3.1%   | 3.02 [0.32, 28.87]           |                              |
| Gaydán 2004           | 0                | 30    | 0            | 28    | Not estimable |                               |                              |
| Molina 2011 ECHO      | 1                | 344   | 0            | 346   | 1.6%   | 3.02 [0.12, 73.81]           |                              |
| Poznianski 2010 TMC278-C204 | 0   | 89    | 0            | 93    | Not estimable |                               |                              |
| van den Berg-Wolf 2008 | 20              | 111   | 18           | 117   | 55.2%  | 1.17 [0.65, 2.09]            |                              |
| van Leth 2004 2NN     | 7                | 400   | 16           | 607   | 40.1%  | 0.68 [0.29, 1.60]            |                              |

Total (95% CI) 1312 1531 100.0% 1.06 [0.66, 1.68]

| Total events | 31 35 |

Heterogeneity: Chi² = 2.44, df = 3 (P = 0.49); I² = 0%
Test for overall effect: Z = 0.23 (P = 0.82)

### disease progression or death

| Study or Subgroup     | efavirenz Events | Total | NNRTI Events | Total | Weight | Risk Ratio M-H, Fixed, 95% CI | Risk Ratio M-H, Fixed, 95% CI |
|-----------------------|------------------|-------|--------------|-------|--------|------------------------------|------------------------------|
| Gaydán 2004           | 0                | 30    | 0            | 28    | Not estimable |                               |                              |
| van den Berg-Wolf 2008 | 34              | 111   | 23           | 117   | 61.0%  | 1.56 [0.98, 2.47]            |                              |
| van Leth 2004 2NN     | 10               | 400   | 18           | 607   | 39.0%  | 0.64 [0.39, 1.18]            |                              |

Total (95% CI) 541 752 100.0% 1.28 [0.66, 1.90]

| Total events | 44 41 |

Heterogeneity: Chi² = 1.85, df = 1 (P = 0.17); I² = 46%
Test for overall effect: Z = 1.23 (P = 0.22)

### pVL<50 copies/ml at weeks 48-52

| Study or Subgroup     | NNRTI Events | Total | efavirenz Events | Total | Weight | Risk Ratio M-H, Fixed, 95% CI | Risk Ratio M-H, Fixed, 95% CI |
|-----------------------|--------------|-------|------------------|-------|--------|------------------------------|------------------------------|
| Cohen 2011 THRIVE     | 291          | 340   | 276            | 338   | 26.3%  | 1.05 [0.98, 1.12]            |                              |
| Molina 2011 ECHO      | 267          | 346   | 265            | 344   | 27.1%  | 1.00 [0.94, 1.07]            |                              |
| Núñez 2002 SENC      | 23           | 36    | 23             | 31    | 2.3%   | 0.86 [0.62, 1.20]            |                              |
| Poznianski 2010 TMC278-C204 | 74     | 93    | 72             | 89    | 7.0%   | 0.98 [0.80, 1.25]            |                              |
| van den Berg-Wolf 2008 | 64           | 117   | 54             | 111   | 5.3%   | 1.12 [0.97, 1.45]            |                              |
| van Leth 2004 2NN     | 407          | 607   | 200            | 408   | 32.0%  | 0.98 [0.98, 1.04]            |                              |

Total (95% CI) 1539 1313 100.0% 1.00 [0.96, 1.04]

| Total events | 1146 990 |

Heterogeneity: Chi² = 4.55, df = 5 (P = 0.47); I² = 0%
Test for overall effect: Z = 0.08 (P = 0.94)

### discontinuation of the therapy due to adverse events

| Study or Subgroup     | efavirenz Events | Total | NNRTI Events | Total | Weight | Risk Ratio M-H, Fixed, 95% CI | Risk Ratio M-H, Fixed, 95% CI |
|-----------------------|------------------|-------|--------------|-------|--------|------------------------------|------------------------------|
| Cohen 2011 THRIVE     | 25              | 388   | 15           | 340   | 10.0%  | 1.46 [0.78, 2.72]            |                              |
| Gaydán 2004           | 2               | 30    | 2            | 28    | 1.3%   | 0.93 [0.14, 6.18]            |                              |
| Molina 2011 ECHO      | 27              | 344   | 8            | 346   | 5.0%   | 3.39 [1.56, 7.37]            |                              |
| Núñez 2002 SENC      | 4               | 31    | 3            | 36    | 1.7%   | 1.55 [0.38, 6.39]            |                              |
| Poznianski 2010 TMC278-C204 | 8     | 89    | 8             | 93    | 4.9%   | 1.04 [0.41, 2.66]            |                              |
| van den Berg-Wolf 2008 | 20             | 111   | 16           | 117   | 9.7%   | 1.32 [0.72, 2.41]            |                              |
| van Leth 2004 2NN     | 63             | 400   | 136           | 607   | 67.4%  | 0.70 [0.54, 0.92]            |                              |

Total (95% CI) 1393 1567 100.0% 1.01 [0.82, 1.24]

| Total events | 149 168 |

Heterogeneity: Chi² = 18.71, df = 6 (P = 0.005); I² = 66%
Test for overall effect: Z = 0.08 (P = 0.95)

---

Fig 2. Forest plot of comparison: efavirenz vs other NNRTI added to the background regimen.

doi:10.1371/journal.pone.0124279.g002
two studies comprised data only for 48 weeks of treatment: GS-236-014, and SINGLE. Most studies included patients with plasma viral load baseline of more than 5,000 copies/ml (only SPRING-1 [35–36] and SINGLE [37] study included patients with pVL > 1,000 copies/ml). Protocol 004 part II [31–32] study assessed four different doses of raltegravir, however while only 400 mg of raltegravir twice a day is consistent with product characteristics, data for this dosage was included in the meta-analysis. After 48-weeks of treatment in Protocol 004 part II, raltegravir arms were combined and all group of patients were given 400 mg twice a day of raltegravir, therefore, data for 96 weeks were shown for all patients initially assigned raltegravir irrespective of the initial dose. Data for discontinuation of treatment due to clinical and laboratory adverse events from Protocol 004 part II study were combined [32]. SPRING-1 trial assessed three different doses of dolutegravir, however, since the study findings showed that 50 mg dolutegravir once daily is the most appropriate dose, data only for this dose were included in meta-analysis. Results of the present meta-analysis showed no statistically significant differences between efavirenz vs. integrase strand transfer inhibitor added to the background regimen for the following outcomes: death (RR = 1.24; 95% CI: 0.33–4.61; p > 0.05) and proportion of patients with pVL < 50 copies/ml at week 96 (RR = 1.04; 95% CI: 0.99–1.09; p > 0.05). Statistically significant more patients treated with integrase strand transfer inhibitor achieved plasma viral load < 50 copies/ml at week 48 (RR = 1.06; 95% CI: 1.03–1.10; p < 0.05), while in terms of toxicity higher risk of discontinuation of therapy due to adverse events was reported when an efavirenz-based regimen were used (RR = 2.30; 95% CI: 1.60–3.31; p < 0.05), Fig 3.

Effectiveness of adding efavirenz vs ritonavir-boosted protease inhibitor (bPI) to the background regimen

Fifteen studies were included in the comparison of efavirenz vs ritonavir-boosted protease inhibitor (bPI) added to the background regimen: Albini 2012 [38], CLASS [39], M03-613 [40], A5202 [41], LAKE [42], Honda 2011 [43], NORTHIV [44–46], SUPPORT [47], TRIZEFAL [48], ADVANZ [49], ALTAIR [50], PHISIDA II [51], A5142 [52], Sierra-Madero 2010 [53], substudy of SISTHER [54–55]. Lopinavir and atazanavir were used as protease inhibitors in eight and five trials, respectively, while amprenavir, indinavir and fosamprenavir were used in single studies, all of them were ritonavir-boosted. Six trials lasted 48–52 weeks, but the follow-ups of the remaining studies were longer (up to 36 months). Four studies additionally included patients with a limited previous exposure to HAART therapy (PHISIDA II [50], A5202 [41], CLASS [39], and SUPPORT [46]). Studies were heterogeneous in regard to the baseline plasma HIV RNA level (>1000 to >10,000 copies/ml), although, in many studies baseline plasma viral load was not a criterion of patient’s inclusion. In Albini 2012 study, the changes of GFR (glomerular filtration rate) during therapy were the primary endpoint [38]. With regard to TRIZEFAL [48] study, it was not possible to meta-analyze the efficacy outcomes due to their inconsistency with other trials, likewise in the substudy of SISTHER trial where plasma viral load was measured only at week 28 [54–55]. In the M03-613 study [40], after 24 weeks of combined therapy with 2 NRTI and lopinavir/ritonavir, the nucleoside reverse transcriptase inhibitor backbone was discontinued. That means 48-week results reflected a comparison of 2 NRTI + efavirenz and two-drug regimen of lopinavir/ritonavir without NRTI background and therefore, data from M03-613 trial [40] were not sufficiently homogeneous for inclusion in the current meta-analysis. The A5202 study did not provide information about the total number of patients in separate groups in whom measurement of pVL < 50 copies/ml was performed at week 48 and 96, thus inclusion of this data in the current meta-analysis was not possible [41]. In NORTHIV trial, the results of the study were combined from both PI-based regimen [44–46]. No statistically significant differences between efavirenz and PI-based regimen were
# Efavirenz in HIV-Infected ART-Naive Patients

**Fig 3.** Forest plot of comparison: efavirenz vs InSTI added to the background regimen.

| Study or Subgroup | efavirenz | InSTI | Risk Ratio M-H, Fixed, 95% CI |
|-------------------|-----------|-------|-------------------------------|
| Cohen 2011        | 0         | 23    | Not estimable                 |
| Lennox 2009/2010 STARTMRK | 0 202 | 2 281 | 0.20 [0.01, 4.13]            |
| Sax 2012 GS-US-236-0102 | 2 352 | 1 348 | 1.98 [0.18, 21.71]           |
| Stellbrink 2013 SPRING-1 | 0 50  | 0 51  | Not estimable                 |
| Walmisley 2013 SINGLE | 2 419 | 0 414 | 4.94 [0.24, 102.80]          |

Total (95% CI): 1126 / 1142 = 100.0% 1.24 [0.33, 4.61]

Total events 4 / 3

Heterogeneity χ² = 2.34, df = 2 (P = 0.31); P = 15%

Test for overall effect: Z = 0.32 (P = 0.75)

**pVL<50 copies/ml at week 48**

| Study or Subgroup | efavirenz | InSTI | Risk Ratio M-H, Fixed, 95% CI |
|-------------------|-----------|-------|-------------------------------|
| Cohen 2011        | 43        | 48    | 2.7% 1.08 [0.88, 1.34]        |
| Lennox 2009/2010 STARTMRK | 241 201 | 220 262 | 1.65 [0.98, 1.13]           |
| Markowitz 2007/2009 | 36 41    | 35 39  | 1.01 [0.98, 1.20]            |
| Sax 2012 GS-US-236-0102 | 305 348 | 296 352 | 1.04 [0.98, 1.11]           |
| van Lucassen 2012 SPRING-1 | 46 51    | 41 50  | 1.10 [0.94, 1.29]            |
| Walmisley 2013 SINGLE | 384 414 | 338 419 | 1.09 [0.93, 1.26]           |

Total (95% CI): 1183 / 1164 = 100.0% 1.06 [1.03, 1.10]

Total events 1035 / 957

Heterogeneity χ² = 1.74, df = 5 (P = 0.88); P = 0%

Test for overall effect: Z = 3.51 (P = 0.0004)

**pVL<50 copies/ml at week 96**

| Study or Subgroup | InSTI | efavirenz | Risk Ratio M-H, Fixed, 95% CI |
|-------------------|-------|-----------|-------------------------------|
| Lennox 2009/2010 STARTMRK | 238 281 | 223 262 | 37.3% 1.03 [0.94, 1.11] |
| Markowitz 2007/2009 | 133 160 | 113 132 | 8.7% 0.99 [0.85, 1.15] |
| Stellbrink 2013 SPRING-1 | 45 51    | 36 50  | 6.1% 1.23 [1.10, 1.50] |
| Zitopeka 2013 GS-US-236-0102 | 293 348 | 287 352 | 47.9% 1.03 [0.97, 1.10] |

Total (95% CI): 840 / 722 = 100.0% 1.94 [0.99, 1.09]

Total events 699 / 578

Heterogeneity χ² = 3.16, df = 3 (P = 0.37); P = 5%

Test for overall effect: Z = 1.52 (P = 0.13)

**discontinuation of the therapy due to adverse events**

| Study or Subgroup | efavirenz | InSTI | Risk Ratio M-H, Fixed, 95% CI |
|-------------------|-----------|-------|-------------------------------|
| Cohen 2011        | 1         | 23    | 0.0% 6.13 [0.26, 144.02] |
| Lennox 2009/2010 STARTMRK | 17 282 | 9 261  | 22.7% 1.88 [0.85, 4.15] |
| Markowitz 2007/2009 | 1 36     | 3 160  | 2.9% 1.40 [0.15, 13.12] |
| Stellbrink 2013 SPRING-1 | 5 50     | 2 51  | 5.0% 2.55 [0.52, 12.54] |
| Walmisley 2013 SINGLE | 42 419   | 10 414 | 25.4% 4.15 [2.11, 8.18] |
| Zitopeka 2013 GS-US-236-0102 | 24 352 | 17 349 | 43.1% 1.40 [0.76, 2.55] |

Total (95% CI): 1164 / 1302 = 100.0% 2.30 [1.60, 3.31]

Total events 90 / 41

Heterogeneity χ² = 6.38, df = 5 (P = 0.27); P = 22%

Test for overall effect: Z = 4.50 (P = 0.00001)

Fig 3. Forest plot of comparison: efavirenz vs InSTI added to the background regimen.
observed when the primary efficacy endpoints were analyzed: death (RR = 1.05; 95% CI: 0.84–1.32; p > 0.05) and disease progression defined in three studies as an occurrence of AIDS-defining events (RR = 1.18; 95% CI: 0.88–1.58; p > 0.05). There were also no statistically significant differences between the analyzed groups (efavirenz vs. ritonavir-boosted PI, both added to the background therapy) in the proportion of patients with plasma viral loads below 50 copies/ml at weeks 48–52 (RR = 0.94; 95% CI: 0.86–1.04; p > 0.05) and at weeks 96–104 (RR = 0.98; 95% CI: 0.80–1.19; p > 0.05), Fig 4.

Results of meta-analysis showed that the risk of discontinuation of treatment due to its intolerance was comparable for both arms, without statistically significant differences (RR = 1.16; 95% CI: 0.87–1.55; p > 0.05), and the risk of grade 3/4 adverse events was similar in both groups (RR = 0.85; 95% CI: 0.57–1.25; p > 0.05), Fig 5.

Effectiveness of adding efavirenz vs CC chemokine receptor type 5 (CCR5) antagonist added to the background regimen

Three trials were included in the comparison of efavirenz vs. CCR5 antagonists, both added to the background regimen in the treatment of HIV-infected antiretroviral-naive patients: MERIT [56–57], ASCENT [58], Landovitz 2008 [59]. Three different CCR5 antagonists were assessed in the above studies: maraviroc [56–57], aplaviroc [58] and vicriviroc [59]. Since clinical studies investigating aplaviroc were discontinued due to cases of hepatotoxicity identified during phase II and III studies (including ASCENT study) [60] and currently this agent is not authorized for marketing in the United States and the European Union, results of ASCENT study were excluded from the present analysis. Unfortunately, it was not possible to meta-analyze the results of MERIT [56–57] and Landovitz 2008 [59] trials due to inconsistent efficacy and safety outcomes measured in the above-mentioned studies. It should be noted that results of the Landovitz 2008 study [59] showed higher rates of virologic failure in vicriviroc groups (25 mg and 50 mg once a day) compared with efavirenz group, suggesting that higher doses of vicriviroc should be investigated in the future clinical trials. Results from MERIT study were described in two references where data for 48-week and 96-week follow-up periods were reported [56–57]. Results for 96-week follow-up were assessed post-hoc in population of 614 patients with CCR5-tropic (R5) HIV-1 that was confirmed with greater sensitivity assay that during randomization [57]. Results of the present analysis (based on MERIT study results, data not shown) revealed no statistically significant differences between efavirenz and maraviroc added to the 2 NRTI for the clinical outcomes: death (RR = 1.00; 95% CI: 0.06–15.88; p > 0.05) and disease progression defined as an occurrence of C category events indicating a development of AIDS (RR = 1.99; 95% CI: 0.76–5.26; p > 0.05) at week 48. Likewise, risk of death in the two treatment arms did not differ statistically for 96-week follow-up period (RR = 1.50; 95% CI: 0.25–8.90; p > 0.05). No statistically significant differences were observed between efavirenz and maraviroc in regard to virological outcomes: plasma viral load below 50 copies/ml at week 48 (RR = 0.94; 95% CI: 0.85–1.04; p > 0.05) and at week 96 (RR = 0.94; 95% CI: 0.83–1.07; p > 0.05). Comparison of efavirenz and CCR5 antagonist in terms of toxicity showed no statistically significant differences between the analyzed regimens in the risk of grade 3/4 adverse events at week 48 (RR = 1.23; 95% CI: 0.94–1.61; p > 0.05) and at week 96 (RR = 1.16; 95% CI: 0.91–1.47; p > 0.05), however, a significantly higher risk of discontinuation of therapy due to adverse events was observed during treatment with efavirenz-based regimen (RR = 3.26; 95% CI: 1.86–5.70; p < 0.05), which was confirmed for both 48 and 96-week follow-up periods.
**death**

| Study or Subgroup | efavirenz Events | bPI Events | Total | Weight | M-H, Fixed, 95% CI | Risk Ratio M-H, Fixed, 95% CI |
|-------------------|------------------|------------|-------|--------|---------------------|-------------------------------|
| Anderson 2013 | 2 | 77 | 2 | 162 | 1.0% | 2.10 [0.30, 14.66] |
| Bartlett 2006 | 1 | 97 | 2 | 96 | 1.6% | 0.49 [0.05, 5.37] |
| Daar 2011 | 17 | 922 | 14 | 926 | 10.8% | 1.22 [0.60, 2.48] |
| Echeverria 2010 LAKE | 0 | 63 | 0 | 63 | Not estimable | |
| Honda 2011 | 0 | 36 | 1 | 35 | 1.2% | 0.32 [0.01, 7.70] |
| Kumar 2013 SUPPORT | 0 | 50 | 1 | 51 | 1.2% | 0.34 [0.01, 8.15] |
| Miró 2010 ADVANZ | 4 | 34 | 1 | 31 | 0.8% | 3.65 [0.43, 30.69] |
| Pulis 2010 ALTAIR | 2 | 114 | 0 | 105 | 0.4% | 4.61 [0.22, 94.90] |
| Ratsela 2010 PHISIDA II | 108 | 888 | 102 | 883 | 79.2% | 1.03 [0.89, 1.33] |
| Sierra-Madero 2010 | 2 | 95 | 5 | 94 | 3.9% | 0.40 [0.08, 1.99] |

Total (95% CI) 2376 2446 100.0% 1.05 [0.84, 1.32]

Test for overall effect: Z = 0.42 (P = 0.67)

**disease progression**

| Study or Subgroup | efavirenz Events | bPI Events | Total | Weight | M-H, Fixed, 95% CI | Risk Ratio M-H, Fixed, 95% CI |
|-------------------|------------------|------------|-------|--------|---------------------|-------------------------------|
| Bartlett 2006 CLASS | 5 | 97 | 2 | 96 | 2.6% | 2.47 [0.49, 12.44] |
| Miró 2010 ADVANZ | 6 | 34 | 5 | 31 | 6.8% | 1.09 [0.37, 3.23] |
| Ratsela 2010 PHISIDA II | 50 | 888 | 69 | 883 | 90.5% | 1.15 [0.85, 1.57] |

Total (95% CI) 1019 1010 100.0% 1.18 [0.88, 1.58]

Test for overall effect: Z = 1.14 (P = 0.26)

**pVL<50 copies/ml at weeks 48-52**

| Study or Subgroup | efavirenz Events | bPI Events | Total | Weight | M-H, Random, 95% CI | Risk Ratio M-H, Random, 95% CI |
|-------------------|------------------|------------|-------|--------|---------------------|-------------------------------|
| Albini 2012 | 48 | 48 | 43 | 43 | 23.1% | 1.00 [0.96, 1.04] |
| Anderson 2013 NORTHIV | 119 | 162 | 66 | 77 | 16.7% | 0.96 [0.75, 0.98] |
| Echeverria 2010 LAKE | 40 | 63 | 36 | 63 | 7.6% | 1.11 [0.84, 1.48] |
| Honda 2011 | 27 | 35 | 28 | 36 | 9.0% | 0.99 [0.77, 1.27] |
| Miró 2010 ADVANZ | 26 | 31 | 32 | 34 | 13.2% | 0.98 [0.75, 1.06] |
| Pulis 2010 ALTAIR | 93 | 101 | 97 | 109 | 20.3% | 1.03 [0.94, 1.12] |
| Sierra-Madero 2010 | 50 | 94 | 87 | 95 | 10.0% | 0.75 [0.60, 0.95] |

Total (95% CI) 534 456 100.0% 0.94 [0.86, 1.04]

Test for overall effect: Z = 1.18 (P = 0.24)

**pVL<50 copies/ml at weeks 96-104**

| Study or Subgroup | efavirenz Events | bPI Events | Total | Weight | M-H, Random, 95% CI | Risk Ratio M-H, Random, 95% CI |
|-------------------|------------------|------------|-------|--------|---------------------|-------------------------------|
| Bartlett 2006 CLASS | 56 | 96 | 66 | 97 | 21.0% | 0.88 [0.69, 1.07] |
| Honda 2011 | 24 | 35 | 20 | 36 | 14.1% | 1.23 [0.85, 1.78] |
| Kumar 2013 SUPPORT | 33 | 51 | 33 | 50 | 17.8% | 0.98 [0.74, 1.30] |
| Miró 2010 ADVANZ | 22 | 31 | 32 | 34 | 19.9% | 0.75 [0.59, 0.98] |
| Riddler 2008 A5142 | 225 | 253 | 193 | 250 | 27.2% | 1.15 [1.06, 1.25] |

Total (95% CI) 466 467 100.0% 0.98 [0.80, 1.21]

Test for overall effect: Z = 0.24 (P = 0.81)

**Fig 4. Forest plot of comparison: efavirenz vs ritonavir-boosted PI (bPI) added to the background regimen-efficacy data.**

doi:10.1371/journal.pone.0124279.g004
Discussion

The choice of the first-line therapy (initial therapy) is determined by various considerations, which include severity of infection, drug tolerability, presence of drug-resistant mutations in non-treated populations, pregnancy or availability of drugs. The cost of therapy is also an important factor, especially in low-resource countries [61]. Difficulties in finding the optimal treatment option for HIV-infected patients which would provide optimal efficacy, durability of antiretroviral activity, tolerability and convenient dosing schedule are reflected by numerous antiretroviral regimens evaluated in clinical trials. Among the initial regimens, the most preferred by clinical experts is a backbone combination of two NRTIs—tenofovir disoproxil fumarate and emtricitabine plus an active drug from one of the following classes: NNRTI (efavirenz), PI (ritonavir-boosted atazanavir, ritonavir-boosted darunavir) or InSTI (raltegravir, dolutegravir) [6–8]. The recommended alternative regimens consist of active drugs which represent the following classes: NNRTI (rilpivirine and nevirapine), PI (fosamprenavir/ritonavir, lopinavir/ritonavir), InSTI (elvitegravir/cobicistat) and CCR5 antagonist (maraviroc) [6–8].

Efavirenz is one of the most commonly used antiretroviral drugs and is one of the preferred treatment options for HIV-infected antiretroviral-naive (ART-naive) patients [62]. To our
knowledge, this is the first such a broad systematic review containing meta-analysis comparing efavirenz-based therapy with other currently recommended antiretroviral regimens used to treat antiretroviral-naive HIV-infected adult patients. Our report is also the most recent systematic review regarding efavirenz-based regimens evaluated in randomized controlled trials conducted in population of HIV-infected patients previously untreated with antiretroviral therapy.

According to the current guidelines for the use of antiretroviral agents during the initial therapy of HIV-infected patients, comparisons were made between efavirenz and drugs from 4 different classes: NNRTI (other than efavirenz), ritonavir-boosted PI (bPI), InSTI and CCR5, all of them added to the backbone regimen. Our meta-analysis demonstrated that efficacy of all regimens based on the above-mentioned drugs were comparable, the analysis did not show any differences in terms of clinical endpoints (death or disease progression usually defined as an occurrence of AIDS-defining events). In terms of virological response (decline in plasma viral load to the predefined levels at week 48) only comparison of efavirenz vs. InSTI showed a statistically significant difference favoring integrase strand transfer inhibitor while in other analysis differences were not statistically significant. The results of the individual studies included in our comparison of efavirenz vs. integrase strand transfer inhibitors showed a trend toward a better effect of InSTI on virological response at week 48. Above effect in the individual studies was not statistically significant probably due to the small number of patients (studies: GS-236-014 [28], SPRING-1 [35–36], Protocol 004 part II [31–32]) while results of SINGLE [37] trial that recruited more than 800 patients showed a statistically significant difference favoring InSTI in comparison with efavirenz. Integrase strand transfer inhibitors are a promising group of antiretroviral agents. Results of a recent FLAMINGO study showed that dolutegravir was superior to darunavir plus ritonavir, both with combination with NRTIs in treatment of HIV-infected ART-naive patients [63]. It is worth noting that, given the results of the latest research Department of Health and Human Services (DHHS) added dolutegravir in combination with selected NRTIs as one of the preferred options in ART-naive HIV-infected patients [6].

Our results are generally in agreement with meta-analysis performed by the other authors. Mbuagbaw et al. [64] found no differences in efficacy between efavirenz and nevirapine-based therapy (irrespective of the dosage of nevirapine) applied as an initial treatment for the antiretroviral-naive, HIV-infected patients. Efavirenz and nevirapine compared as a part of a three-drug combination were both equally effective in the suppression of HIV infection for such outcomes as: virological success (percentage of participants achieving undetectable plasma HIV RNA concentration over time), clinical progression of AIDS and mortality. Similar observations were reported by Siegfried et al. [61] who demonstrated equivalent efficacy of two NNRTIs (efavirenz and nevirapine-based regimens) for the treatment of HIV infection in antiretroviral treatment-naive adults [61]. We also confirmed results of our previous meta-analysis where no statistically significant differences were shown between nevirapine and efavirenz in terms of disease progression or death as well as virological response and safety profile in antiretroviral-naive HIV-infected patients [65]. However meta-analysis of Pillay et al. showed that efavirenz-treated, treatment-naive patients were more likely to achieve virologic success than patients treated with nevirapine (RR = 1.04; 95% CI: 1.00–1.08) [66]. It should be mentioned, that about half of the trials included to the above-mentioned meta-analysis [66] involved patients co-infected with tuberculosis, and hence these studies were excluded from our meta-analysis.

In terms of virological response our results are in contrast with the direct meta-analysis of Chou et al. which showed that NNRTI-based regimens in ART-naive patients were better than PI-based regimens with regard to decrease of plasma HIV RNA levels below 50 copies/ml [67]. However, the probable explanation for the observed discrepancy between both meta-analyses...
is that different trials were included. Chou et al. combined all studies evaluating drugs that belong to a NNRTI or PI class, while our analysis was consistent with the current guidelines for the first-line treatment. For this reason, we excluded studies assessing regimens not recommended for the first-line treatment (for example delavirdine as an NNRTI or unboosted-PI).

In addition, the meta-analysis of Chou et al. [67] was performed in 2006, since that time the results of about 15 new RCTs have been published, which we could include in the current meta-analysis. Therefore, some of the regimens analyzed in our meta-analysis were not included in the previous one (for example rilpivirine as NNRTI or ritonavir-boosted atazanavir). Restriction to regimens including the older generation of PIs (that may be less potent) in the previous meta-analysis, could be the explanation of the observed differences between NNRTI and PI-based regimens [67], not confirmed by our cumulative results.

It should be noticed that the current meta-analysis described in this report has several limitations. The most important is that we were not able to aggregate results from studies comparing efavirenz and CCR5 antagonist-based regimens, due to inconsistent efficacy and safety outcomes measured in the included studies. For this reason, comparison of efavirenz and CCR5 antagonists was based on data from only one study, in which maraviroc was evaluated. The trial that was excluded from our meta-analysis (due to non-homogeneous outcomes in both trials evaluating CCR5 inhibitors) assessed vicriviroc, an experimental CCR5 antagonist, that is still in the phase of clinical trials and has not yet been approved for the treatment of HIV-infected, antiretroviral-naive patients. In addition, we did not identify the trials comparing a ritonavir-boosted darunavir (recommended by current guidelines) with efavirenz-based regimen in the analyzed population.

Another limitation was related to heterogeneity of the included studies regarding background regimens, baseline characteristics of randomized patients (especially proportions of patients in various stages of the disease), duration of follow-up periods, baseline median HIV RNA level, as well as differences in the definitions of the analyzed endpoints. While relatively low baseline HIV RNA plasma level is considered to be a predictive factor of virologic success during antiretroviral therapy [6,20], it should be noticed that the baseline plasma viral load varied within studies included in the meta-analysis (for example: pVL in studies included in the comparison of efavirenz and other NNRTI ranged from >5 000 copies/ml [15,17–19,24] to 100 000 copies/ml [20]). However, it should be emphasized that relatively large number of trials included in the individual meta-analysis (especially comparing NNRTI and ritonavir-boosted PI), reduced the influence of potential confounders and made the obtained results reliable.

Additionally, the absence of subgroup analysis in dependence on background regimens, due to a limited number of trials suitable for inclusion into separate comparisons, is another limitation of the present meta-analysis. A previous systematic review demonstrated that efavirenz is the most effective when administrated on a tenofovir and emtricitabine backbone [68], that is consistent with the currently published treatment guidelines for antiretroviral-naive patients [6,8]. The above-mentioned results indicate that backbone regimen may affect the results obtained in separate comparisons (when background regimen consisted of 2 NRTI was different in both treatment arms). However, it should be mentioned, that in most included studies backbone regimen was the same in the compared groups. Moreover, in the most recently published trials (assessing rilpivirine or InSTI), the already established and recommended combination of tenofovir and emtricitabine was used as a backbone regimen.

In this systematic review, we did not analyze trials including patients with comorbid, clinically relevant illnesses. There were several reasons for that, mainly the existence of separate recommendations for these groups of patients. Firstly, clinical guidelines recommend efavirenz as an initial ART regimen for patients on rifampin-based treatment for tuberculosis (while other
NNRTIs as nevirapine are not recommended) [7–8]. Moreover, co-administration of rifampin and PIs (with or without ritonavir boosting) is not recommended [6], that restricts treatment options in those group of patients mostly to efavirenz-based therapy. Secondly, a systematic review and meta-analysis of studies, in which HIV/HCV co-infected patients were included, showed that statistically less patients with HIV/HCV co-infection reached plasma viral load <50 copies/ml at week 48 than HIV mono-infected patients (68.2% vs 80.4% respectively) [69]. In addition, patients with concurrent illnesses are at higher risk of adverse events leading to therapy discontinuation, moreover, a larger number of pills they have to take probably decreases the adherence to assigned treatment. What is more, interactions between the administered drugs should be also taken into consideration. We decided that the above factors could increase the heterogeneity of the included studies and decrease reliability of cumulative results of the meta-analysis and therefore we excluded such studies from our review.

The overall toxicity profile of efavirenz-based and other assessed regimens was comparable. However, a significantly higher risk of the discontinuation of therapy due to adverse events was observed in efavirenz group when compared with integrase inhibitors and CCR5 antagonists. It should be noticed that comparison with CCR5 antagonists was based on data from only one study and the reliability of these results is limited (further studies may change these preliminary conclusions). We did not analyze particular adverse events observed during treatment with of efavirenz-based regimens, however, neuropsychiatric adverse events were the most common side effects associated with efavirenz, that can limit the use of this agent [62]. Four systematic reviews regarding neuropsychiatric adverse events associated with efavirenz treatment have been recently published [62,70–72]. A systematic review performed by Kenedi et al. [62] demonstrated high rates of neuropsychiatric side effects among efavirenz-treated patients; vivid dreams, insomnia and mood changes were reported in approximately 50% of patients initiating treatment with efavirenz [62]. In antiretroviral-naive patients receiving efavirenz-based therapy, significantly higher rates of grade 1–4 neurological and psychiatric adverse events were reported compared to other regimens based on protease inhibitors or other NNRTIs [70]. Unfortunately, due to a different classification system used to access the above side effects reported in particular studies, limited data were suitable for comparison [70]. It should be noticed that most of the efavirenz-associated neuropsychiatric adverse events were generally mild and transient in nature. Based on the findings from clinical trials, efavirenz should not be initiated in patients with a history of severe psychiatric disorders, active mental illnesses, depressive symptom or severe sleep disorders in spite of the convenience of once daily dosing [62,70]. Recently published meta-analysis showed that patients receiving efavirenz were more likely to experience severe central nervous system-related adverse events than nevirapine [71]. Clinical experts indicate the need for large randomized controlled trials to determine if the neuronal toxicity induced by efavirenz results in clinically significant neurological impairment [72]. Despite the increased risk of neuropsychiatric adverse events in some of predisposed patients, efavirenz seems to have an acceptable safety profile. What is important, a meta-analysis of Gazzard et al. 2010 demonstrated no statistically significant differences between efavirenz and other first-line antiretroviral agents in regards to the incidence of any other side effects even such as severe or life-threatening adverse events [69].

Some authors suggest increased risk of suicide during efavirenz treatment. Recent meta-analysis of four randomized controlled trials showed an increased rate of suicidality events (including also suicidal ideation) in patients treated with efavirenz-containing antiretroviral regimen compared to other regimens. However while only completed/attempted suicides where assessed only a trend towards higher rates of above events in efavirenz group was reported [73]. Mentioned results were not confirmed in observational study where no higher death rates from suicide amongst patients treated with efavirenz than other regimens were reported [74].
What is more no evident association between efavirenz use and suicidality was reported when data from Food and Drug Administration Adverse Event Reporting System (FAERS) database were analyzed [75].

Results of the current meta-analysis strengthen the current clinical guidelines where active drugs from four different classes of antiretroviral agents are recommended. However, it should be noticed that some regimens can be recommended for a specific population of patients. For example rilpivirine is now recommended in patients with pretreatment HIV RNA ≤100,000 copies/mL, while the combination of elvitegravir/cobicistat/tenofovir/emtricitabine is recommended for patients with pre-treatment creatinine clearance >70 mL/min [6].

In conclusion, the results of the present meta-analysis support the current clinical guidelines for antiretroviral-naive, HIV-infected patients. Efavirenz-based therapy should be considered as one of the most preferred treatment options in ART-naive patients, however it should be prescribed with caution in patients with underlying psychiatric conditions. Results of recent studies suggests good efficacy and beneficial safety profile of drugs from new classes of antiretroviral agents (integrase inhibitors, CCR5 antagonists) compared with other initial regimens used nowadays in clinical practice for the treatment of HIV-infected patients, however more data from further, reliable RCTs are needed to confirm above results.

Supporting Information
S1 PRISMA Checklist. (DOC)

Author Contributions
Conceived and designed the experiments: PK JK. Performed the experiments: PK JK. Analyzed the data: JK PK. Contributed reagents/materials/analysis tools: PK JK. Wrote the paper: JK PK AP.

References
1. Murphy EL, Collier AC, Kalish LA, Assmann SF, Para MF, Flaniqan TP, et al. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med. 2001; 135: 17–26. PMID: 11434728
2. Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 1998; 352: 1725–1730. PMID: 9848347
3. Gulick RM, Ribaudo HJ, Shikuma CM, Lustgarten S, Squires KE, Meyer WA 3rd. AIDS Clinical Trials Group Study A5095 Team. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med. 2004; 350(18): 1850–1861. PMID: 15115831
4. Gallant J, DeJesus E, Ambris J, Pozniak A, Gazzard B, Campo RE, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med. 2006; 354: 251–260. PMID: 16421366
5. Vrouwenraets SM, Wit FW, van Tongeren J, Lange JM. Efavirenz: a review. Expert Opin Pharmacother. 2007; 8(6): 851–871. PMID: 17425480
6. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available: http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed October 06, 2014.
7. Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA. 2012; 308(4): 387–402. doi: 10.1001/jama.2012.7961 PMID: 22820792
8. WHO. Consolidated guidelines on general HIV care and the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. June 2013.
9. Moher D, Liberati A, Tetzlaff J, Altman DG, The Prisma Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Int J Surg. 2010; 8(5): 336–341. doi: 10.1016/j.ijssu.2010.02.007 PMID: 20171303

10. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions Version 5.1.0 [up-dated March 2011]. Cochrane Collaboration and John Wiley. 2011. Available: www.cochrane-handbook.org.

11. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds JM, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17(1): 1–12. PMID: 8721797

12. Albert JM, Conway B, Ioannidis JP, Reichelderfer P. Statistical issues for HIV surrogate endpoints: point/counterpoint. An NIAID workshop. Stat Med. 1998; 17(21): 2435–2462. PMID: 9819838

13. Raboud JM, Montaner JS, Conway B, Rae S, Reiss P, Vella S, et al. Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy. AIDS 1998; 12(13): 1619–1624. PMID: 9764780

14. Raboud JM, Rae S, Montaner JS. The Incas Avanti Study Groups. Predicting HIV RNA virologic outcome at 52-weeks follow-up in antiretroviral clinical trials. J Acquir Immune Defic Syndr. 2000; 24(5): 433–439. PMID: 11035613

15. Cohen CJ, Andrade-Villanueva J, Clotet B, Fourie J, Johnson MA, Ruxrungtham K, et al. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomized, non-inferiority trial. Lancet 2011; 378(9787): 229–237. doi: 10.1016/S0140-6736(11)60983-5 PMID: 21763935

16. Gaytán JJA, Garza ERZ, Garcia MC, Chavez SBV. Nevirapine or efavirenz in combination with two nucleoside analogues in HIV-infected antiretroviral-naive patients. Med Int Mex. 2004; 20(1): 29–33.

17. Gazzard B, Duvivier C, Zagler C, Castagna A, Hill A, van Delft Y, et al. Phase 2 double-blind, randomised trial of etravirine versus efavirenz in treatment-naive patients: 48-week results. AIDS 2011; 25(18): 2249–2258. doi: 10.1097/QAD.0b013e32834c4c06 PMID: 21881478

18. Nelson M, Stellbrink HJ, Podzamczer D, Banhegyi D, Gazzard D, Hill A, et.al. A comparison of neuropsychiatric adverse events during 12 weeks of treatment with etravirine and efavirenz in a treatment-naive, HIV-1-infected population. AIDS 2011; 25(3): 335–340. doi: 10.1016/S0213-4604(11)60936-7 PMID: 21150563

19. Molina JM, Cahn P, Grinsztejn B, Lazzarin A, Mills A, Saag M, et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet 2011; 378(9787): 238–246. doi: 10.1016/S0140-6736(11)60936-7 PMID: 21763936

20. Nuñez M, Soriano V, Martin-Carbonero L, Barrios AA, Barreiro PP, Blanco F, et al. SENC (Spanish efavirenz vs. nevirapine comparison) trial: a randomized, open-label study in HIV-infected naive individuals. HIV Clin Trials. 2002; 3(3): 186–194. PMID: 12032877

21. Pozniak AL, Morales-Ramírez J, Katabira E, Reynolds JM, Santoscoy M, et al. Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial. AIDS 2010; 24(1): 55–65. doi: 10.1097/QAD.0b013e3283030e03 PMID: 1986964

22. van den Berg-Wolf M, Hullsiek KH, Peng G, Kozal MJ, Novak RM, Chen L, et al. Virologic, immunologic, clinical, safety, and resistance outcomes from a long-term comparison of efavirenz-based versus nevirapine-based antiretroviral regimens as initial therapy in HIV-1-infected persons. HIV Clin Trials. 2008; 9(6): 324–336. doi: 10.1310/hct0905-324 PMID: 18977721

23. MacArthur RD, Novak RM, Peng G, Chen L, Xiang Y, Hullsiek KH, et al. A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial. Lancet 2006; 368(9553): 2125–2135. PMID: 17174704

24. van Leth F, Panunthak P, Ruxrungtham K, Baraldi E, Miller S, Gazzard B, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 2004; 363(9417): 1253–1263. PMID: 15094269

25. Vernaizza P, Wang C, Pozniak A, Weil E, Pullik P, Cooper DA, et al. Efficacy and safety of lersivirine (UK-453,061) versus efavirenz in antiretroviral treatment-naive HIV-1-infected patients: week 48 primary analysis results from an ongoing, multicenter, randomized, double-blind, phase IIb trial. J Acquir Immune Defic Syndr. 2013; 62(2): 171–179. doi: 10.1097/QAI.0b013e31827a2ba2. PMID: 23328090

26. Wester CW, Thomas AM, Bussmann H, Moyo S, Makhema JM, Gaolathe T, et al. Non-nucleoside reverse transcriptase inhibitor outcomes among combination antiretroviral therapy-treated adults in
Cohen C, Elion R, Ruane P, Shamblaw D, DeJesus E, Rashbaum B, et al. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection. AIDS 2011; 25(6): F7–F12. doi: 10.1097/QAD.0b013e328345766f PMID: 21412057

Lennox JL, DeJesus E, Lazzarin A, Pollard RB, Madruga JV, Berger DS, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naïve patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009; 374(9692): 796–806. doi: 10.1016/S0140-6736(09)60918-1 PMID: 19647866

Lennox JL, DeJesus E, Berger DS, Lazzarin A, Pollard RB, Madalho Madruga JV, et al. Raltegravir Versus Efavirenz Regimens in Treatment-Naive HIV-1-Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses. J Acquir Immune Defic Syndr. 2010; 55(1): 39–48. doi: 10.1097/QAI.0b013e3181e1da1287 PMID: 20404738

Markowitz M, Nguyen BY, Gotuzzo E, Mendo F, Ratanasuwan W, Kovacs C, et al. Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naïve patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr. 2009; 49(6): 111–118. PMID: 17721395

Markowitz M, Nguyen BY, Gotuzzo E, Mendo F, Ratanasuwan W, Kovacs C, et al. Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naïve patients with HIV-1 infection. J Acquir Immune Defic Syndr. 2009; 52(3): 350–356. doi: 10.1097/QAI.0b013e31811b064b0 PMID: 19648823

Sax PE, DeJesus E, Mills A, Zolopa A, Cohen C, Wohl D, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet 2012; 379(9835): 2439–2448. doi: 10.1016/S0140-6736(12)60917-9 PMID: 22748591

Zolopa A, Sax PE, DeJesus E, Mills A, Cohen C, Wohl D, et al. A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/ emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results. J Acquir Immune Defic Syndr. 2013; 63(1): 96–100. doi: 10.1097/QAI.0b013e318289545c PMID: 23392460

van Lunzen J, Maggiolo F, Arribas JR, Rakhammerova A, Yeni P, Young B, et al. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. Lancet Infect Dis. 2012; 12 (2): 111–118. doi: 10.1016/S1473-3099(11)70290-0 PMID: 22018760

Stellbrink HJ, Reynes J, Lazzarin A, Voronin E, Pulido F, Felizarta F, et al. Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study. AIDS 2013; 27(11): 1771–1778. doi: 10.1097/QAD.0b013e3283612419 PMID: 23807273

Walmsley SL, Antela A, Clumec N, Duiculescu D, Eberhard A, Gutiérrez F, et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013; 369(19): 1807–1818. doi: 10.1056/NEJMoa1215541 PMID: 24195548

Albini L, Cesana BM, Motta D, Foca E, Gotti D, Calabresi A, et al. A randomized, pilot trial to evaluate glomerular filtration rate by creatinine or cystatin C in naive HIV-infected patients after tenofovir/emtricitabine combination therapy. J Acquir Immune Defic Syndr. 2006; 43(3): 284–292. PMID: 16967040

Bartlett JA, Johnson J, Herrera G, Sosa N, Rodriguez A, Liao Q, et al. Long-term results of initial therapy with abacavir and Lamivudine combined with Efavirenz, Amprenavir/Ritonavir, or Stavudine. J Acquir Immune Defic Syndr. 2006; 43(3): 284–292. PMID: 16967040

Cameron DW, da Silva BA, Arribas JR, Myers MA, Bellos NC, Gilmore N, et al. A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy. J Infect Dis. 2008; 198(2): 234–240. doi: 10.1086/589622 PMID: 18540803

Daar ES, Tierney C, Fischl MA, Sax PE, Mollan K, Budhathoki C, et al. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med. 2011; 154(7): 445–456. doi: 10.7326/0003-4819-154-7-201104050-00316 PMID: 21320923

Echeverría P, Negredo E, Carosi G, Gálvez J, Gómez JL, Ocampo A, et al. Similar antiviral efficacy and tolerability between efavirenz and lopinavir/ritonavir, administered with abacavir/lamivudine (Kivexa), in antiretroviral-naive patients: a 48-week, multicentre, randomized study (Lake Study). Antiviral Res. 2010; 85(2): 403–408. doi: 10.1016/j.antiviral.2009.11.008 PMID: 19941906
43. Honda M, Ishisaka M, Ishizuka N, Kimura S, Oka S. Japanese Anti-HIV-1 QD Therapy Study Group. Open-label randomized multicenter selection study of once daily antiretroviral treatment regimen comparing ritonavir-boosted atazanavir to efavirenz with fixed-dose abacavir and lamivudine. Intern Med. 2011; 50(7): 699–705. PMID: 21467701

44. Josephson F, Andersson MC, Flamholc L, Gisslén M, Hågberg L, Ormaasen V, et al. The relation between treatment outcome and efavirenz, atazanavir or lopinavir exposure in the NORTIVI trial of treatment-naive HIV-1 infected patients. Eur J Clin Pharmacol. 2010; 66(4): 349–357. doi: 10.1007/s00228-009-0763-2 PMID: 19967342

45. Edén A, Andersson LM, Andersson O, Flamholc L, Josephson F, Nilsson S, et al. Differential effects of efavirenz, lopinavir/ritonavir, and atazanavir/ritonavir on the initial viral decay rate in treatment naive HIV-1-infected patients. AIDS Res Hum Retroviruses. 2010; 26(5): 533–540. doi: 10.1089/aid.2009.0177 PMID: 20455766

46. Andersson LM, Vesterbacka J, Blaxhult A, Flamholc L, Nilsson S, Ormaasen V, et al. Lopinavir/ritonavir, atazanavir/ritonavir, and efavirenz in antiretroviral-naive HIV-1-infected individuals over 144 weeks: An open-label randomized controlled trial. Scand J Infect Dis. 2013; 45: 545–550. doi: 10.3109/00365548.2012.756985 PMID: 23294034

47. Kumar P, DeJesus E, Huhn G, Sloan L, Small CB, Edelstein H, et al. Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in under-represented, antiretroviral-naive, HIV-infected patients (SUPPORT): 96-week results. BMC Infect Dis. 2013; 13(1): 269. doi: 10.1186/1471-2334-13-269

48. Mallojas J, Pich J, Peñaranda M, Domingo P, Knobel H, Pedrol E, et al. Induction therapy with trizivir plus efavirenz or lopinavir/ritonavir followed by trizivir alone in naïve HIV-1-infected adults. AIDS 2008; 22(3): 377–384. doi: 10.1097/QAD.0b013e3282f3db2c PMID: 18195564

49. Miró JM, Manzardo C, Pich J, Domingo P, Ferrer E, Arribas JR, et al. Immune reconstitution in severely immunosuppressed antiretroviral-naive HIV type 1 infected patients using a nonnucleoside reverse transcriptase inhibitor-based or a boosted protease inhibitor-based antiretroviral regimen: three-year results (The Advanz Trial): a randomized, controlled trial. AIDS Res Hum Retroviruses. 2010; 26(7): 747–757. doi: 10.1089/aid.2009.0105 PMID: 20624069

50. Puls RL, Srasuebkul P, Petoumenos K, Boesecke C, Duncombe C, Duncombe C, et al. Efavirenz versus boosted atazanavir or zidovudine and abacavir in antiretroviral treatment-naive, HIV-infected subjects: week 48 data from the Altair study. Clin Infect Dis. 2010; 51(7): 855–864. doi: 10.1086/656363 PMID: 20735258

51. Phidisa II Writing Team for Project Phidisa, Ratsela A, Polis M, Dhlomo S, Emery S, Grandits G, Khabo P, et al. A randomized factorial trial comparing 4 treatment regimens in treatment-naive HIV-infected persons with AIDS and/or a CD4 cell count <200 cells/µL in South Africa. J Infect Dis. 2010; 202(10):1529–1537. PMID: 20942650

52. Riddler SA, Haubrich R, DiRienzo AG, Peeples L, Powderly WG, Klingman KL, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med. 2008; 358(20): 2095–2106. doi: 10.1056/NEJMoa074609 PMID: 18480202

53. Sierra-Madero J, Villasís-Keever A, Méndez P, Mosqueda-Gómez JL, Torres-Escobar I, Gutiérrez-Escolano F, et al. Prospective, randomized, open label trial of Efavirenz vs Lopinavir/Ritonavir in HIV+ treatment-naive subjects with CD4+<200 cell/mm3 in Mexico. J Acquir Immune Defic Syndr. 2010; 53(5):582–588. doi: 10.1097/QAI.0b013e3181e8a4a1 PMID: 20090545

54. Torti C, Quiros-Roldón E, Regazzi M, Antinori A, Patroni A, Villani P, et al. Early virological failure after tenofovir + didanosine + efavirenz combination in HIV-positive patients upon starting antiretroviral therapy. Antivir Ther. 2005; 10(4): 505–13. PMID: 16038476

55. Torti C, Quiros-Roldán ME, Cologni G, Nichelatti M, Ceresoli F, Pinti M, et al. Plasma HIV load and pro-viral DNA decreases after two standard antiretroviral regimens in HIV-positive patients naïve to antiretrovirals. Curr HIV Res. 2008; 6(1):43–48. PMID: 18288974

56. Cooper DA, Heera J, Goodrich J, Tawadrous M, Saag M, Dejesus E, et al. Maraviroc versus efavirenz, both in combination with zidovudine/lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. J Infect Dis. 2010; 201(6): 803–813. doi: 10.1086/650697 PMID: 20151839

57. Sierra-Madero J, Di Perri G, Wood R, Saag M, Frank I, Craig C, et al. Efficacy and safety of maraviroc versus efavirenz, both with zidovudine/lamivudine: 96-week results from the MERIT study. HIV Clin Trials. 2010; 11(3): 125–132. doi: 10.1310/hct1103-125 PMID: 20736149

58. Currier J, Lazzarin A, Sloan L, Clumeck N, Slims J, McCarty D, et al. Antiviral activity and safety of aplaviroc with lamivudine/zidovudine in HIV-infected, therapy-naive patients: the ASCENT (CCR102881) study. Antivir Ther. 2008; 13(2): 287–306. PMID: 18505181
59. Landovitz RJ, Angel JB, Hoffmann C, Horst H, Opravil M, Long J, et al. Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection. J Infect Dis. 2008; 198(8): 1113–1122. doi:10.1086/592052 PMID: 18783318
60. Crabb C. GlaxoSmithKline ends aplaviroc trials. AIDS 2006; 20(5): 641. PMID: 16514292
61. Siegfried NL, Van Deventer PJ, Mahomed FA, Rutherford GW. Stavudine, lamivudine and nevirapine combination therapy for treatment of HIV infection and AIDS in adults. Cochrane Database Syst Rev. 2006; 2: CD004535. PMID: 16625606
62. Kenedi CA, Goforth HW. A systematic review of the psychiatric side-effects of efavirenz. AIDS Behav. 2011; 15(8): 1803–1818. doi: 10.1007/s10461-011-9939-5 PMID: 21484283
63. Clotet B, Feinberg J, van Lunzen J, Khuong-Josses MA, Antinori A, Dumitru I, et al. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet 2014; 383(9936): 2222–2231. doi: 10.1016/S0140-6736(14)60084-2 PMID: 24698485
64. Mbuagbaw LC, Irlam JH, Spaulding A, Rutherford GW, Siegfried N. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naive individuals. Cochrane Database Syst Rev. 2010; 12: CD004246. doi: 10.1002/14651858.CD004246.pub3 PMID: 21154355
65. Kawalec P, Kryst J, Mikrut A, Płc A. Nevirapine-based regimens in HIV-infected antiretroviral-naive patients: systematic review and meta-analysis of randomized controlled trials. PLoS One 2013; 8(10): e76587. doi: 10.1371/journal.pone.0076587 PMID: 24116123
66. Pillay P, Ford N, Shubber Z, Ferrand RA. Outcomes for efavirenz versus nevirapine-containing regimens for treatment of HIV-1 infection: a systematic review and meta-analysis PLoS One 2013; 8(7): e68995. doi: 10.1371/journal.pone.0068995 PMID: 23894391
67. Chou R, Fu R, Huffman LH, Korthuis PT. Initial highly-active antiretroviral therapy with a protease inhibitor versus a non-nucleoside reverse transcriptase inhibitor: discrepancies between direct and indirect meta-analyses. Lancet 2006; 368(9546): 1503–1515. PMID: 17071284
68. Bartlett JA, Chen SS, Quinn JB. Comparative Efficacy of Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Combination with Efavirenz: Results of Systematic Overview. HIV Clin Trial. 2007; 8(4): 221–226. PMID: 17720662
69. Pulido F, Hill A, van Delft, Moecklinghoff C. Impact of hepatitis C co-infection on response to antiretroviral treatment. AIDS Rev. 2012; 14(2): 124–131. PMID: 22627608
70. Gazzard B, Balkin A, Hill A. Analysis of neuropsychiatric adverse events during clinical trials of efavirenz in antiretroviral-naive patients: a systematic review. AIDS Rev. 2010; 12(2): 67–75. PMID: 20571601
71. Shubber Z, Calmy A, Andrieux-Meyer I, Vitoria M, Renaud-Théry F, Shaffer N, et al. Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis. AIDS 2013; 27(9): 1403–1412. doi: 10.1097/QAD.0b013e32835f1db0 PMID: 23343913
72. Decloedt EH, Maartens G. Neuronal toxicity of efavirenz: a systematic review. Expert Opin Drug Saf. 2013; 12(6): 841–846. doi: 10.1517/14740338.2013.823396 PMID: 23889591
73. Molan KR, Smurzynski M, Eron JJ, Daar ES, Campbell TB, Sax PE, et al. Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data. Ann Intern Med. 2014; 161(1): 1–10. doi: 10.7326/M14-0293 PMID: 24979445
74. Smith C, Ryom L, Monforte Ad, Reiss P, Mocroft A, El-Sadr W, et al. Lack of association between use of efavirenz and death from suicide: evidence from the D:A:D study. J Int AIDS Soc. 2014; 17(4 Suppl 3): 19512. doi: 10.7448/IAS.17.4.19512 PMID: 25394021
75. Napoli AA, Wood JJ, Coubitis JJ, Soitkar AM, Seekins DW, Tilson HH, et al. No evident association between efavirenz use and suicidality was identified from a disproportionality analysis using the FAERS database. J Int AIDS Soc. 2014; 17: 19214. doi: 10.7448/IAS.17.1.19214 PMID: 25192857